GlassScriptPhysician profile
Tamara Hopkins
NPI 1144226465
$6,439.07
in general payments reported to CMS, 2019-2025
47 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $265 · 2021: $662 · 2022: $894 · 2023: $1,214 · 2024: $1,576 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.44 |
| Education | $265.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $695.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $673.52 | 2019-2025 | Opdivo, Opdualag, Sprycel |
| Celgene Corporation | $607.92 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $508.51 | 2019-2022 | |
| Abbvie INC. | $470.44 | 2019-2025 | |
| Daiichi Sankyo INC. | $466.29 | 2019-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $447.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.85 | 2019-2024 | Imfinzi, Lynparza, Enhertu |
| Array Biopharma INC | $218.11 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $182.29 | 2019-2023 | |
| Emd Serono, INC. | $158.51 | 2021-2025 | Tepmetko |
| Merck Sharp & Dohme LLC | $148.05 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $136.84 | 2019-2024 | Lunsumio, Polivy, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $136.62 | 2023-2025 | Libtayo |
| Seagen INC. | $99.00 | 2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Hopkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.